SAB Biotherapeutics (NASDAQ:SABS) Stock Price & Analysis

–

USD

–(–)

Open

$3.945

Prev. Close

$3.42

High

$4.07

Low

$3.865

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

CEOSamuel J. Reich

SectorHealthcare

IndustryBiotechnology

Employees86

IPO DateFeb 9, 2021

ExchangeNASDAQ

Exchange NameNASDAQ

CurrencyUSD

Headquarters & Contact

Address777 W 41st St.

City / State / ZIPMiami Beach, FL, 33140

CountryUnited States

Phone605 679 6980

Websitehttps://www.sab.bio

SAB Biotherapeutics, Inc.

Company Profile

Recently from Cashu